Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBITDA (2016 - 2025)

Amicus Therapeutics filings provide 16 years of EBITDA readings, the most recent being $15.9 million for Q4 2025.

  • On a quarterly basis, EBITDA changed 0.16% to $15.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $32.8 million, a 31.81% increase, with the full-year FY2025 number at $36.7 million, up 22.8% from a year prior.
  • EBITDA hit $15.9 million in Q4 2025 for Amicus Therapeutics, down from $34.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $34.3 million in Q3 2025 to a low of -$75.3 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$23.3 million (2023), compared with a mean of -$21.9 million.
  • Biggest five-year swings in EBITDA: surged 532.58% in 2024 and later crashed 163.3% in 2025.
  • Amicus Therapeutics' EBITDA stood at -$72.1 million in 2021, then surged by 41.33% to -$42.3 million in 2022, then soared by 91.28% to -$3.7 million in 2023, then surged by 532.58% to $16.0 million in 2024, then dropped by 0.16% to $15.9 million in 2025.
  • The last three reported values for EBITDA were $15.9 million (Q4 2025), $34.3 million (Q3 2025), and -$9.5 million (Q2 2025) per Business Quant data.